Natalie Landeck, PhD, received her doctoral degree in neuroscience from the Lund University, Sweden, in 2016. As part of her doctoral training, she studied modifications and toxicity of alpha-synuclein - a protein that accumulates in the brains of Parkinson's disease patients. She applied a broad variety of tools ranging from viral vector-mediated in vivo models to novel protein assays. In 2017, she joined the Laboratory of Neurogenetics (LNG) at the National Institute on Aging (NIA) as a postdoctoral fellow. Dr. Landeck currently studies the effects of mutations in genes associated with neurodegeneration in in vivo models. Additionally, she focuses on the phosphorylation of alpha-synuclein, its function and interaction with other disease-causing proteins and the underlying processes that lead to Parkinson's disease pathology.